Dr. Tagawa Discusses the Development of Immunotherapy in Urothelial Cancer

Scott T. Tagawa, MD, MS, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discusses the development of immunotherapy for patients with urothelial cancer.

Platinum-based chemotherapy has been a successful treatment for patients with urothelial cancer, but immunotherapies—particularly PD-1/PD-L1 antibodies—have captured much of the recent attention in the field, states Tagawa.

One-quarter of patients with urothelial cancer see durable responses with immunotherapy. Now, trials are focused on combination regimens, explains Tagawa.